The Acute Effects of Blood Flow Restriction on Ankle Muscle Reaction Time and Proprioception in Healthy Individuals
NCT ID: NCT07307339
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
24 participants
INTERVENTIONAL
2025-09-01
2026-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
Arm 2: Sham Comparator - Sham Blood Flow Restriction Participants perform the same balance and proprioception tests with sham blood flow restriction at 20 mmHg.
This is a randomized crossover study, and all participants complete both conditions in a randomized order.
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood Flow Restriction
Participants perform balance/proprioception tests under lower limb blood flow restriction at % 60 AOP.
Blood Flow Restriction
Arm Description: Participants perform balance/proprioception tests under lower limb blood flow restriction at % 60 AOP.
Sham BFR
Sham BFR Description: Participants perform the same tests with sham(20 mmHg) blood flow restriction
Sham Blood Flow Restriction
Sham BFR Description: Participants perform the same tests with sham(20 mmHg) blood flow restriction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Flow Restriction
Arm Description: Participants perform balance/proprioception tests under lower limb blood flow restriction at % 60 AOP.
Sham Blood Flow Restriction
Sham BFR Description: Participants perform the same tests with sham(20 mmHg) blood flow restriction
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No known neuromuscular or cardiovascular disease
Exclusion Criteria
* Presence or history of varicose veins, hypertension, diabetes mellitus, or pulmonary disease
* History of pulmonary embolism or deep vein thrombosis
* Use of medications affecting the central nervous or cardiovascular systems
* Use of oral contraceptives or anticoagulants
* Pregnancy
* Open wounds or significant scar tissue at the cuff application site
* History of lower extremity musculoskeletal injury or surgery
* Any neurological, vascular, or systemic condition that may interfere with test performance
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uludag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Melike Tugran
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ufuk sekir
Role: STUDY_DIRECTOR
Department of Sports Medicine, Bursa Uludağ University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uludag University
Bursa, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-15/31
Identifier Type: -
Identifier Source: org_study_id